A rapid, antibiotic susceptibility test for multidrug-resistant, Gram-negative bacterial uropathogens using the biochemical assay, DETECT.

Szczegóły
Abstrakt

Tytuł:: A rapid, antibiotic susceptibility test for multidrug-resistant, Gram-negative bacterial uropathogens using the biochemical assay, DETECT.
Autorzy:: Jackson N; School of Public Health, Department of Infectious Diseases and Vaccinology, University of California Berkeley, Berkeley, CA, USA. Electronic address: .
Borges CA; School of Public Health, Department of Infectious Diseases and Vaccinology, University of California Berkeley, Berkeley, CA, USA.
Tarlton NJ; Department of Microbiology, BioAmp Diagnostics, Inc., San Carlos, CA, USA.
Resendez A; Department of Chemistry, BioAmp Diagnostics, Inc., San Carlos, CA, USA.
Milton AK; Department of Chemistry, BioAmp Diagnostics, Inc., San Carlos, CA, USA.
de Boer TR; Department of Chemistry, BioAmp Diagnostics, Inc., San Carlos, CA, USA.
Butcher CR; School of Public Health, Department of Infectious Diseases and Vaccinology, University of California Berkeley, Berkeley, CA, USA.
Murthy N; Department of Bioengineering, University of California Berkeley, Berkeley, CA, USA.
Riley LW; School of Public Health, Department of Infectious Diseases and Vaccinology, University of California Berkeley, Berkeley, CA, USA. Electronic address: .
Źródło:: Journal of microbiological methods [J Microbiol Methods] 2021 Mar; Vol. 182, pp. 106160. Date of Electronic Publication: 2021 Feb 04.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
Język:: English
Imprint Name(s):: Original Publication: Amsterdam, The Netherlands : Elsevier Biomedical, c1983-
MeSH Terms:: Drug Resistance, Multiple, Bacterial*
Escherichia coli*/isolation & purification
Escherichia coli*/metabolism
Klebsiella pneumoniae*/isolation & purification
Klebsiella pneumoniae*/metabolism
Escherichia coli Infections/*microbiology
Klebsiella Infections/*microbiology
Urinary Tract Infections/*microbiology
Bacterial Proteins/metabolism ; Humans ; Proof of Concept Study ; beta-Lactamases/metabolism
References:: Int J Antimicrob Agents. 2014 Oct;44(4):295-300. (PMID: 25223936)
J Microbiol Methods. 2018 Jan;144:37-43. (PMID: 28970054)
Dtsch Arztebl Int. 2010 May;107(21):361-7. (PMID: 20539810)
Nat Rev Urol. 2017 May;14(5):296-310. (PMID: 28248946)
J Urol. 2011 Jan;185(1):148-53. (PMID: 21074208)
BMC Bioinformatics. 2011 Mar 17;12:77. (PMID: 21414208)
Lab Med. 2017 Dec 22;49(1):35-40. (PMID: 29161406)
Nat Rev Urol. 2010 Dec;7(12):653-60. (PMID: 21139641)
Chembiochem. 2018 Oct 18;19(20):2173-2177. (PMID: 30079487)
J Glob Infect Dis. 2018 Jan-Mar;10(1):19-21. (PMID: 29563719)
J Clin Microbiol. 2018 Jul 26;56(8):. (PMID: 29769277)
Antimicrob Agents Chemother. 2015;59(6):3281-9. (PMID: 25801565)
Clin Microbiol Rev. 2018 Feb 14;31(2):. (PMID: 29444952)
Ann Emerg Med. 2001 Nov;38(5):505-12. (PMID: 11679861)
Clin Microbiol Infect. 2015 Mar;21(3):251.e1-8. (PMID: 25698659)
J Antimicrob Chemother. 2010 Mar;65(3):490-5. (PMID: 20071363)
Diagn Microbiol Infect Dis. 2017 Nov;89(3):222-229. (PMID: 28865741)
Antimicrob Agents Chemother. 2007 Jun;51(6):1987-94. (PMID: 17387156)
Clin Infect Dis. 2004 Apr 15;38(8):1150-8. (PMID: 15095222)
J Antimicrob Chemother. 2015 Apr;70(4):1219-25. (PMID: 25473028)
Clin Microbiol Newsl. 2018 Jun 1;40(11):87-95. (PMID: 32287688)
Microb Drug Resist. 2020 Aug 19;:. (PMID: 32830997)
Foodborne Pathog Dis. 2019 Dec;16(12):813-822. (PMID: 31411497)
J Hosp Med. 2014 Apr;9(4):232-8. (PMID: 24464783)
Int J Antimicrob Agents. 2019 Jul;54(1):49-54. (PMID: 30986523)
Ther Adv Urol. 2019 May 02;11:1756287219832172. (PMID: 31105774)
World J Urol. 2020 Nov;38(11):2669-2679. (PMID: 31925549)
J Microbiol Methods. 2018 Jan;144:44-46. (PMID: 29056446)
J Chemother. 2017 Dec;29(sup1):10-18. (PMID: 29271734)
Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):487-96. (PMID: 25311986)
Clin Infect Dis. 2013 Mar;56(5):641-8. (PMID: 23150211)
J Family Med Prim Care. 2015 Apr-Jun;4(2):265-8. (PMID: 25949979)
J Med Microbiol. 2012 Jul;61(Pt 7):968-974. (PMID: 22493279)
J Microbiol Immunol Infect. 2015 Jun;48(3):269-75. (PMID: 24239065)
Biotechnol J. 2019 Jan;14(1):e1700750. (PMID: 30024110)
Front Cell Infect Microbiol. 2020 Jul 15;10:308. (PMID: 32760676)
mBio. 2019 Oct 29;10(5):. (PMID: 31662453)
Am J Med. 2002 Jul 8;113 Suppl 1A:5S-13S. (PMID: 12113866)
Scand J Infect Dis. 2014 Nov;46(11):803-8. (PMID: 25262922)
Antimicrob Resist Infect Control. 2017 Dec 6;6:124. (PMID: 29225798)
J Clin Microbiol. 2016 Nov;54(11):2701-2706. (PMID: 27558176)
Antimicrob Agents Chemother. 2019 May 24;63(6):. (PMID: 30936096)
Arch Intern Med. 2002 Mar 11;162(5):600-5. (PMID: 11871930)
J Clin Microbiol. 2015 Aug;53(8):2473-9. (PMID: 25994167)
Postgrad Med. 2020 Apr;132(3):234-250. (PMID: 31608743)
J Infect Public Health. 2020 Apr;13(4):558-563. (PMID: 31685404)
J Antimicrob Chemother. 2017 Jan;72(1):166-171. (PMID: 27703058)
Diagn Microbiol Infect Dis. 2019 Mar;93(3):191-195. (PMID: 30477953)
Clin Infect Dis. 2008 Mar 1;46(5):689-95. (PMID: 18230040)
J Antimicrob Chemother. 2017 Dec 1;72(12):3288-3297. (PMID: 28961934)
Int J Microbiol. 2017;2017:4287547. (PMID: 28630628)
J Chemother. 2017 Dec;29(sup1):2-9. (PMID: 29271736)
Grant Information:: R01 AI117064 United States AI NIAID NIH HHS
Contributed Indexing:: Keywords: Antibiotic resistance; Antimicrobial susceptibility testing; Extended-spectrum β-lactamase; Infectious disease diagnostics; Urinary tract infection
Substance Nomenclature:: 0 (Bacterial Proteins)
EC 3.5.2.6 (AmpC beta-lactamases)
EC 3.5.2.6 (beta-Lactamases)
Entry Date(s):: Date Created: 20210206 Date Completed: 20211001 Latest Revision: 20220302
Update Code:: 20240104
PubMed Central ID:: PMC7925429
DOI:: 10.1016/j.mimet.2021.106160
PMID:: 33548393
: Czasopismo naukowe

Full Text Finder

The increasing prevalence of extended spectrum β-lactamases (ESBLs) and plasmid-mediated AmpC (pAmpC) β-lactamases among Enterobacterales threatens our ability to treat urinary tract infections (UTIs). These organisms are resistant to most β-lactam antibiotics and are frequently multidrug-resistant (MDR). Consequently, they are often resistant to antibiotics used to empirically treat UTIs. The lack of rapid diagnostic and antibiotic susceptibility tests (AST) makes clinical management of UTIs caused by such organisms difficult, as standard culture and susceptibility assays require several days. We have adapted a biochemical detection assay, termed dual-enzyme trigger-enabled cascade technology (DETECT) for rapid detection of resistance (time-to-result of 3 h) to other antibiotics commonly used in treatment of UTIs. DETECT is activated by the presence of CTX-M and pAmpC β-lactamases. In this proof-of-concept study, the adapted DETECT assay (AST-DETECT) has been performed on pure-cultures of Klebsiella pneumoniae and Escherichia coli (48 isolates) expressing ESBL or pAmpC β-lactamases to perform AST for ciprofloxacin (sensitivity 96.9%, specificity 100%, accuracy 97.9%) nitrofurantoin (sensitivity 95.7%, specificity 91.7%, accuracy 94%) and trimethoprim/sulfamethoxazole (sensitivity 83.3%, specificity 100%, accuracy 89.4%). These results suggest that AST-DETECT may be adapted as a potential diagnostic platform to rapidly detect multidrug-resistant E. coli and K. pneumoniae that cause UTI.
(Copyright © 2021 Elsevier B.V. All rights reserved.)

Informacja